瑞舒伐他汀与阿托伐他汀治疗冠心病的临床应用效果比较

Clinical application effect comparison of Rosuvastatin and Atorvastatin in the treatment of coronary heart disease

目的比较瑞舒伐他汀与阿托伐他汀治疗冠心病的临床应用效果。方法选取2018年4月~2019年4月沈阳医学院附属第二医院收治的500例冠心病患者作为研究对象,通过动态化随机分为试验组与对照组,每组各250例。试验组患者采取瑞舒伐他汀治疗,对照组患者采取阿托伐他汀治疗。比较两组患者的临床疗效、心功能指标、血脂水平以及不良反应发生情况。结果试验组患者的治疗总有效率(96.00%)高于对照组(70.00%),差异有统计学意义(P<0.05)。治疗后,两组患者的左室射血分数(LVEF)均高于治疗前,左室舒张末期内径(LVEDD)均低于治疗前,差异有统计学意义(P<0.05);治疗后,试验组患者的LVEF高于对照组,LVEDD低于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者的三酰甘油、总胆固醇、低密度脂蛋白含量均低于治疗前,高密度脂蛋白高于治疗前,差异有统计学意义(P<0.05);治疗后,试验组患者的三酰甘油、总胆固醇、低密度脂蛋白含量低于对照组,高密度脂蛋白含量高于对照组,差异有统计学意义(P<0.05)。试验组患者的不良反应总发生率(4.80%)低于对照组(12.80%),差异有统计学意义(P<0.05)。结论瑞舒伐他汀治疗冠心病患者可提高临床效果,有效改善心功能指标和血脂指标,用药安全性较高,值得临床推广应用。

Objective To compare the clinical effect of Rosuvastatin and Atorvastatin in the treatment of coronary heart disease.Methods A total of 500 patients with coronary heart disease who admitted to the Second Affiliated Hospital of Shenyang Medical College from April 2018 to April 2019 were selected as the research objects and randomly divided into the experimental group and the control group by dynamics,with 250 cases in each group.The experimental group was treated with Rosuvastatin and the control group was treated with Atorvastatin.The clinical efficacy,cardiac function indexes,blood lipid levels and adverse reactions were compared between the two groups of patients.Results The total effective rate of the experimental group(96.00%)was higher than that of the control group(70.00%),and the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of the two groups was higher than that before treatment,the left ventricular end diastolic diameter(LVEDD)of the two groups was lower than that before treatment,and the differences were statistically significant(P<0.05).After treatment,the LVEF of the experimental group was higher than that of the control group,the LVEDD of the experimental group was lower than that of the control group,and the differences were statistically significant(P<0.05).After treatment,the triglyceride,total cholesterol,and low-density lipoprotein of the two groups were lower than those before treatment,high-density lipoprotein contents of the two groups were higher than those before treatment,and the differences were statistically significant(P<0.05).After treatment,triglyceride,total cholesterol,low-density lipoprotein of the experimental group were lower than those of the control group,high-density lipoprotein of the experimental group was higher than that of the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in experimental group(4.80%)was lower than that in the control group(12.80%),and the difference was statistically significant(P<0.05).Conclusion Rosuvastatin in the treatment of patients with coronary heart disease can improve the clinical efficacy,effectively improve blood lipid indexes and cardiac function indexes,and the drug is safer,so it is worthy of clinical promotion and application.